Prenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8

Prenetics (NASDAQ: PRE), parent of health and longevity brand IM8, appointed Brian J. Rosin as U.S. Chief Financial Officer on May 14, 2026.

Rhea-AI Summary

Prenetics (NASDAQ: PRE), parent of health and longevity brand IM8, appointed Brian J. Rosin as U.S. Chief Financial Officer on May 14, 2026. He will lead finance, capital allocation, investor relations support, and financial infrastructure, reporting to CEO Danny Yeung.

Rosin brings nearly 20 years of experience in consumer e-commerce and premium wellness subscriptions. IM8 is active in 40+ countries and is projecting $190–$210 million in 2026 revenue, its second year from launch.

Positive

• IM8 projects $190–$210 million in 2026 revenue in year two
• IM8 products now sold in more than 40 countries
• Appointment of experienced CFO establishes dedicated IM8 finance leadership
• Nearly 20 years of relevant consumer wellness and e-commerce experience added

Negative

• None.

Argus May 14 session

+0.11% close to close Open Argus

Details

News Market Reaction – PRE

On May 14, the day this news came out, PRE closed 0.11% above the previous close.

Data tracked by StockTitan Argus for the May 14 session.

Market Context

This announcement highlights Prenetics’ focus on institutionalizing IM8’s growth by adding an experi...

Analysis

This announcement highlights Prenetics’ focus on institutionalizing IM8’s growth by adding an experienced CFO as the brand targets $190–210M in 2026 revenue across 40+ countries. Recent filings show continued net losses and significant marketing spend, as well as an F-3 registration for 2,360,416 warrant-linked shares. Investors may watch upcoming earnings, progress on IM8’s profitability, warrant exercise activity, and further capital allocation disclosures to assess execution quality.

Key Figures

IM8 2026 revenue guidance: $190–210M IM8 country footprint: More than 40 countries Executive experience: Nearly two decades +5 more

IM8 2026 revenue guidance

$190–210M

Projected IM8 revenue for 2026 in its 2nd year from launch

IM8 country footprint

More than 40 countries

IM8 distribution reach mentioned in CFO appointment release

Executive experience

Nearly two decades

Brian J. Rosin’s financial leadership experience in consumer wellness

Registered resale shares

2,360,416 shares

Class A Ordinary Shares registered on F-3 for resale via Exchange Warrants

Warrant exercise price

$18.00

Exercise price of Exchange Warrants registered on the F-3 shelf

Net loss 2025

$38.7M

Net loss for 2025 from Form 20-F

Selling & marketing 2025

$35.5M (38.5% of revenue)

2025 selling and marketing expenses from Form 20-F

Bitcoin holdings

About 510 Bitcoin

Treasury reserve position disclosed in Form 20-F

Historical Context

5 past events · Latest: May 08

5 events

1. May 08

   Earnings call timing

   24h Move

   +1.8%

   Announcement of Q1 2026 results date and earnings conference call details.

2. May 07

   Sports partnership

   24h Move

   -0.2%

   IM8 named exclusive health supplements partner of Inter Miami CF with equity stake.

3. Apr 28

   Dividend declaration

   24h Move

   -5.3%

   First Horizon declared cash dividends on common and preferred stock.

4. Apr 14

   Impact partnership

   24h Move

   -0.9%

   IM8 Health and Vitamin Angels partnered to address global malnutrition at scale.

5. Apr 02

   Celebrity partnership

   24h Move

   +0.6%

   Giannis Antetokounmpo became IM8 Global Partner and shareholder in multi-year deal.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

direct-to-consumer, private equity-backed, e-Commerce

3 terms

direct-to-consumer financial

"premium consumer health, nutrition, and direct-to-consumer brands joins IM8"

A direct-to-consumer (DTC) model is when a company sells its products or services straight to customers, skipping middlemen like retailers or wholesalers. For investors, DTC matters because it can mean higher profit margins, closer customer relationships and faster feedback—like a baker who sells directly from the shop instead of through a grocery chain—while also exposing the business to costs for marketing, customer support and logistics that affect growth and profitability.

private equity-backed financial

"Wellbeam Consumer Health, a private equity-backed e-Commerce-focused consumer wellness platform"

A company described as private equity-backed is one that is largely owned or controlled by an investment firm that buys businesses, invests money and expertise, and plans to sell them later for a profit. For investors, that matters because such ownership often brings a focus on faster growth, cost cuts, and higher borrowing to finance changes—like a home renovator who borrows to improve a house and then sells it—so outcomes can mean quicker value creation but also higher financial risk and less public transparency.

e-Commerce financial

"a private equity-backed e-Commerce-focused consumer wellness platform"

E-commerce is the buying and selling of goods or services over the internet. It allows people to shop from anywhere at any time, much like an online marketplace. For investors, e-commerce is important because it represents a growing way businesses reach customers, often leading to increased sales and new opportunities in the digital economy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

~ Two-decade veteran of premium consumer health, nutrition, and direct-to-consumer brands joins IM8 to support its rapid global expansion

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced the appointment of Brian J. Rosin as U.S. Chief Financial Officer. Mr. Rosin will be based in the U.S. and will lead the Company's finance organization, reporting to Chief Executive Officer Danny Yeung.   Mr. Rosin's appointment establishes dedicated finance leadership for IM8 to support the Company's growing operations and the rapid global expansion of the IM8 brand.

Mr. Rosin brings nearly two decades of financial leadership in consumer e-Commerce and premium wellness subscription brands, with significant transaction experience including several successful exits. He joins Prenetics at a pivotal moment, as IM8 has become one of the fastest growing supplement brands ever recorded in the industry, is now sold in more than 40 countries, and is projecting $190 million to $210 million in revenue for 2026 in just it’s 2^nd year from launch.

In his new role, Mr. Rosin will be responsible for financial strategy, capital allocation, investor relations support, and the financial infrastructure and unit-economics discipline required to scale a premium consumer health brand from breakout launch to durable, profitable, global category leadership.

Danny Yeung, Co-Founder and Chief Executive Officer of Prenetics, commented: "Brian’s entire career has been spent at the intersection of high growth consumer, premium nutrition, and subscription supplements in e-Commerce. He understands the unit economics, brand-building discipline, and operating cadence required to turn a breakout consumer health product into an enduring, global category leader. As IM8 expands across more than 40 countries and into new daily nutrition formats, Brian's expertise will be invaluable in ensuring the financial discipline and infrastructure behind our growth match the ambition of the brand."

Brian J. Rosin, Chief Financial Officer of IM8, commented: "I've spent nearly two decades helping build premium consumer health brands, and what drew me to IM8 was the data — the unit economics and retention here are unlike anything I've seen in the category. David Beckham as a co-founding partner, world-class athletes as authentic users, science-backed formulations, and an AI-native operating culture make for a rare platform in consumer health. I'm honored to join Danny and the team, and I look forward to building the financial foundation to support IM8's next phase of growth in the United States and globally."

Mr. Rosin joins Prenetics from Wellbeam Consumer Health, a private equity-backed e-Commerce-focused consumer wellness platform, where he served as Chief Financial Officer and Senior Vice President, e-Commerce Operations. In those roles, he led finance and digital commerce across Wellbeam's portfolio of brands, including TruSkin (clean, plant-powered skincare), BioTRUST Nutrition (direct-to-consumer nutrition for healthy aging), Eu Natural (women's botanical supplements), and Penetrex (joint and muscle therapy, divested in 2024). He originally joined TruSkin as CFO in 2020, prior to its acquisition by Wellbeam in 2021. Earlier in his career, he also held CFO roles at NATURELO Premium Supplements, and Rant, Inc. Mr. Rosin holds dual bachelor's degrees, Cum Laude, in Economics and Political Science from Northern Illinois University.

About IM8

IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. IM8's flagship product, Daily Ultimate Essentials, is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is trusted by NBA Champion and two-time MVP Giannis Antetokounmpo, World No. 1 tennis player Aryna Sabalenka, and F1 driver Ollie Bearman. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, surpassing $100 million in annualized recurring revenue within just 11 months and is now sold in more than 40 countries worldwide. IM8 is a subsidiary of Prenetics (NASDAQ: PRE). To learn more, visit www.IM8health.com.

About Prenetics

Prenetics (NASDAQ: PRE) is a leading health sciences company dedicated to advancing human health and longevity. The Company's flagship consumer brand, IM8, co-founded with David Beckham and trusted by NBA superstar Giannis Antetokounmpo, World No. 1 tennis player Aryna Sabalenka and F1 phenom Ollie Bearman, is redefining the premium daily nutrition category through science-backed formulations and global brand partnerships. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, achieving an impressive milestone of surpassing $100 million in annualized recurring revenue within just 11 months of operations, and is now sold in more than 40 countries worldwide.

Investor Relations Contact:

investors@prenetics.com | PRE@mzgroup.us

Angela Cheung Investor Relations / Corporate Finance angela.hm.cheung@prenetics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Prenetics (NASDAQ: PRE) announce about IM8's CFO on May 14, 2026?

Prenetics announced the appointment of Brian J. Rosin as U.S. Chief Financial Officer of IM8. According to Prenetics, he will lead finance, capital allocation, investor relations support, and financial infrastructure for the fast-growing premium health and longevity brand.

Who is Brian J. Rosin, the new IM8 CFO under Prenetics (PRE)?

Brian J. Rosin is a veteran finance leader in consumer health and e-commerce. According to Prenetics, he has nearly two decades of experience with premium wellness subscription brands and has held CFO roles at Wellbeam Consumer Health, TruSkin, NATURELO Premium Supplements, and Rant.

What revenue is IM8 projecting for 2026 under Prenetics (NASDAQ: PRE)?

IM8 is projecting $190 million to $210 million in revenue for 2026. According to Prenetics, this forecast comes in IM8’s second year from launch, reflecting rapid expansion of its premium health and longevity supplements across more than 40 countries.

How does the new IM8 CFO appointment impact Prenetics (PRE) investors?

The appointment adds dedicated financial leadership for IM8’s global growth. According to Prenetics, Brian Rosin will focus on financial strategy, capital allocation, unit economics, and infrastructure, which may help support scalable, profitable expansion of the IM8 brand within the Prenetics portfolio.

What experience does IM8 CFO Brian Rosin bring to Prenetics (PRE)?

Brian Rosin brings extensive transaction and operational experience in consumer wellness. According to Prenetics, he led finance and e-commerce at Wellbeam’s brands such as TruSkin, BioTRUST Nutrition, Eu Natural, and Penetrex, and has worked across premium supplements and direct-to-consumer subscription models.